| Private Placement / Financing Transactions
Procyrion: The company raised $57.7 million in a Series E funding round, including the conversion of $10.0 million of interim financing, on February 5, 2024. The deal was led by Fannin Innovation Studio in partnership with new and existing family/multi-family office investors. The company is an operator of a medical device business that provides treatment options for patients with cardiac and renal impairment. The company is developing the Aortix percutaneous mechanical circulatory support device, a catheter-deployed pump technology that harnesses fluid entrainment to pump blood to address multiple conditions with significant unmet needs.
Abridge: The company raised $150 million of Series C venture funding in a deal led by LightSpeed and Redpoint Ventures on February 23, 2024, putting the company’s pre-money valuation at $700 million. IVP, Spark Capital, Union Square Ventures, Wittington Ventures, CVS Health Ventures, Kaiser Permanente Ventures, Mass General Brigham, Bessemer Venture Partners and Digital Innovation Fund also participated in the round. The company is a developer of an Artificial Intelligence-based healthcare application that restructures medical conversations into notes for patients.
Frontier Medicines: The company raised $80 million of Series C venture funding in a deal led by Deerfield Management and Droia Ventures on February 22, 2024. Galapagos (Biotechnology), MPM BioImpact, RA Capital Management, and DCVC Bio also participated in the round. The company is a developer of a chemoproteomics platform designed to accelerate the development of medicines through machine learning.
Reprieve: The company raised $42 million of Series A venture funding in a deal led by Santé Ventures and Lightstone Ventures on February 21, 2024. Deerfield Management, Arboretum Ventures and Genesis Capital also participated in the round. The company is a developer of an acute decompensated heart failure (ADHF) treatment device.
Vektor Medical: The company raised $29 million of Series A venture funding in a deal led by Solas BioVentures and TVM Capital Life Science on February 19, 2024. The company is a developer of an artificial intelligence-based technology that analyzes and maps cardiac arrhythmias.
restor3d: The company closed on $20.75 million of a $55 million targeted amount of venture funding on February 22, 2024. The company is a developer of 3D-printed implants technology.
Vivacelle Bio: The company raised $20 million of Series B venture funding from undisclosed investors on February 22, 2024. The company is a developer of a novel intravenous resuscitation fluid technology designed to reverse the consequences of hypovolemia and shock.
AZmed: The company raised EUR 15 million of Series A venture funding from TeamPact Ventures, Techstars and Maison Worms on February 20, 2024. The company is a developer of a computer-aided diagnosis tool designed to facilitate physician workflows.
Caresyntax: The company raised $15 million of venture funding from MTIP on February 20, 2024. The company is a developer of a vendor neutral data-driven surgery platform that reduces variability and improves efficiency.
CoRegen: The company raised $14.5 million of venture funding from undisclosed investors on February 21, 2024. The company is a developer of an AI-powered drug discovery platform that accelerates the discovery of new medicines for cancer treatment.
Tagomics: The company raised GBP 6.7 million of venture funding in a deal led by Calculus Capital on February 21, 2024. Illumina Ventures, Agilent Technologies, Mercia Asset Management, Meltwind Advisory, OMX Ventures and IQ Capital Partners also participated in the round. The company is a developer of epigenetic-based chemicals designed for throughput and cost-effective epigenetic biomarker discovery.
Avicenna Biosciences: The company raised $6 million of venture funding in the form of convertible debt from undisclosed investors on February 23, 2024. The company is an operator of a biotechnology business intended to redesign and optimize drug candidates.
MedsEngine: The company raised $5.8 million of venture funding from undisclosed investors on February 20, 2024. The company is a developer of an AI-enabled clinical decision support system designed for the improvement of chronic disease outcomes.
Healionics: The company raised $5.5 million of Series A3 venture funding from Keiretsu Forum and other undisclosed investors on February 20, 2024. The company is an operator of a clinical-stage business intended to improve health, longevity and quality of life for kidney failure patients, while reducing treatment costs.
Avatar Medical: The company raised $5.4 million of venture funding in a deal led by GO Capital (France) on February 19, 2024. Rives Croissance, Cenitz, Acorn Pacific Ventures, and Plug and Play Tech Center also participated in the round. The company is a developer of a virtual reality medical platform designed to create patient avatars to help surgeons visualize medical images.
Immertec: The company raised $3.6 million of venture funding from undisclosed investors on February 23, 2024. The company is a developer of a real-time 3D virtual reality communication platform designed to train physicians in real-time and remotely.
Bioptimus: The company raised $35 million of venture funding on February 19, 2024. The company is a developer of an AI foundation model designed to connect biology at its different scales from molecules to cells, tissues, and whole organisms.
InsightRx: The company raised an undisclosed amount of venture funding from Canadian Imperial Bank of Commerce on February 23, 2024. The company is an operator of a cloud-based clinical decision support platform intended to help clinicians individualize treatment at the point of care.
Sphingotec: The company raised an undisclosed amount of venture funding from Boditech Med on February 21, 2024. The company is a developer of biomarkers intended for the diagnosis, prediction, and monitoring of acute medical conditions, such as heart failure, kidney injury, and circulatory shock.
|
